Expression of the cell proliferation marker, Ki67, indicated that either TRAIL or OSMI-1 treatment alone had little or no effect on the reduction of tumor cell proliferation, whereas the combination treatment caused a dramatic decrease. This evidence concerns the gene TNFSF10 and neoplasm.